Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia

Overview

Journal Haematologica

Specialty Hematology

Date 2017 Aug 12

PMID 28798068

Citations 4

Authors

Paolo Strati

Michael J Keating

Jan A Burger

Susan M OBrien

William G Wierda

Zeev Estrov

Gracy Zacharian

Alessandra Ferrajoli

Affiliations

Soon will be listed here.

Citing Articles

Maintenance therapy for chronic lymphocytic leukaemia.

Lee C, Wu Y, Huang T, Lin C, Zou Y, Cheng J Cochrane Database Syst Rev. 2024; 1:CD013474.

PMID: 38174814 PMC: 10765471. DOI: 10.1002/14651858.CD013474.pub2.

A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.

Lee C, Chen P, Lin C, Wang C, Ho C PLoS One. 2020; 15(1):e0226879.

PMID: 31995577 PMC: 6988939. DOI: 10.1371/journal.pone.0226879.

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.

Gauthier M, Durrieu F, Martin E, Peres M, Vergez F, Filleron T BMC Cancer. 2019; 19(1):809.

PMID: 31412798 PMC: 6694602. DOI: 10.1186/s12885-019-5971-z.

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

Strati P, Takahashi K, Peterson C, Keating M, Thompson P, Daver N Blood Adv. 2019; 3(9):1533-1539.

PMID: 31076409 PMC: 6517659. DOI: 10.1182/bloodadvances.2019031336.

References

Shanafelt T, Ramsay A, Zent C, Leis J, Tun H, Call T . Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 2013; 121(20):4137-41. DOI: 10.1182/blood-2012-12-470005. View

Strati P, Keating M, Wierda W, Badoux X, Calin S, Reuben J . Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013; 122(5):734-7. PMC: 4123325. DOI: 10.1182/blood-2013-04-495341. View

Jain N, OBrien S . Targeted therapies for CLL: Practical issues with the changing treatment paradigm. Blood Rev. 2016; 30(3):233-44. DOI: 10.1016/j.blre.2015.12.002. View

Chang J, Havighurst T, Kim K, Eickhoff J, Traynor A, Kirby-Slimp R . Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. Br J Haematol. 2016; 173(2):283-91. PMC: 5923897. DOI: 10.1111/bjh.13957. View